An observational study in Organ Dysfunction Scores and Hypophosphatemia, sponsored by University of Tartu. Completed at 1 site in Estonia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by University of Tartu · Observational
This study will address two specific research questions simultaneously:
The aim is to recruit 20 ICUs and 1500 ICU patients. Sites will recruit all consecutive adult patients to a maximum of 120 patients or a maximum recruitment period of 8 weeks, whichever comes first. Daily data collection on gastrointestinal signs and symptoms as well as phosphate values and management will be collected during ICU stay for maximum of 7 days. 28 and 90 day mortality and days free of organ support will be the main outcomes. Secondary outcomes include prevalence of hypo- and hyperphosphatemia and description of their management.
Patient population All consecutive adult patients that are admitted to participating ICU during a recruitment period of maximum 8 weeks.
Duration of the study for the individual patient:
Baseline characteristics will be collected at ICU admission/study inclusion Daily data include routine data on organ dysfunctions and organ support therapies and specific data on phosphate where available.
Outcome data include 28 and 90 days mortality, and days free of organ support by day 28.
53 studies on the registry are indexed under Hypophosphatemia; 16 are open to participants now.
This study's enrollment of 2,681 is above the median of 105 across 26 observational studies indexed under Hypophosphatemia.
Browse Hypophosphatemia studies →University of Tartu is the lead sponsor of 46 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All consecutive adult patients that are admitted to participating ICU during a recruitment period of maximum 8 weeks. In all included patients data on organ dysfunctions will be collected, in patients from sites with routine serum phosphate measurements additional data on phosphate values and management will be collected (inclusion in the Phosphate part of the study).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
We collect routine daily data on GI signs and symptoms and calculate the score (GIDS). We collect serum phosphate values as measured in routine practice of participating sites.
Also known as: Phosphate levels
90 days mortality
Survival status at 90 days after ICU admission
Time frame: 90 days
28 days mortality
Survival status at 28 days after ICU admission
Time frame: 28 days
Days free of organ support
Days alive and free of organ support (including parenteral nutrition-free days) by day 28
Time frame: 28 days
Prevalence of phosphate disorders at ICU admission
Prevalence of hypo- and hyperphosphatemia on ICU admission
Time frame: Day of ICU admission (day 1)
Incidence of phosphate disorders during seven days of ICU stay
Incidence of hypo- and hyperphosphatemia during seven days of ICU stay
Time frame: 7 days
The amount of phosphate administered
The amount of phosphate administered to patients with hypophosphatemia
Time frame: 7 days
Change in serum phosphate level in response to phosphate supplementation
Chenge in serum phosphate level in response to phosphate supplementation (correction/overcorrection/no correction)
Time frame: 7 days
Plan to share: Undecided
Ran from Jan 2024 to primary completion in Dec 2024, 11 months.
Of 14 observational studies under Hypophosphatemia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Tartu